Start with the number that defines the worry: a franchise this concentrated lives and dies by its patent timeline. Cystic fibrosis is caused by a broken protein called CFTR, and Vertex's drugs — CFTR modulators — fix or compensate for that protein. When the foundational patents expire, the cliff looms.
But a cliff is only as close as the newest defensible patent is far. And the 2024 record shows Vertex was still arming the estate. Its grant US12168009B2 covers modulators of the cystic fibrosis transmembrane conductance regulator — a fresh modulator claim issued late in the year, naming a long list of specific compounds.
Formulation patents extend the runway too. Vertex's US11951212B2 covers pharmaceutical compositions for treating CFTR-mediated diseases. A new formulation doesn't protect the old molecule, but it can protect the version patients actually take.
By the numbers, the pattern is the standard franchise-defense playbook: as the first-generation compound ages toward its cliff, the company issues claims on next-generation modulators and improved formulations, shifting the protected center of gravity forward. The cliff for the original drug stays where it is; the cliff for the franchise keeps moving out.
The honest caveat: a new patent on a new compound only matters if patients move to that compound. Re-arming the estate buys exclusivity on the latest drug, not on the molecule that built the franchise. Whether that translates to durable revenue depends on whether the newer modulators are meaningfully better.
So the Cliff Watch read for Vertex's CFTR estate: the 2024 filings show an active defense, not a company sitting still ahead of an expiry. The franchise cliff is being managed compound by compound — which is exactly what you'd expect from a company whose entire value rests on it.